Stabilized liquid anti-RSV antibody formulations
View Patent ↗The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
1. A method for preventing a symptom of a respiratory syncytial virus (RSV) infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab or an antigen-binding fragment thereof; and (b) histidine, wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by high performance size exclusion chromatography (HPSEC).
2. A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of 23 mM to 27 mM; and (c) glycine at a concentration of less than 2 mM, wherein said formulation has a pH of between about 5.5 to 6.5, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
3. A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 95 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of about 25 mM; and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of between about 5.5 to 6.5, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
4. A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 95 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of about 25 mM; and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of between about 5.8 to 6.2 and does not contain mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
5. The method of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/kg, at least 85 mg/ml, at least 90 mg/ml or at least 95 mg/ml.
6. The method of claim 3 or 4 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 100 mg/kg.
7. The method of claim 1 or 2 , wherein said palivizumab or antigen-binding fragment thereof is at a concentration of at least 100 mg/ml.
8. The method of claim 7 , wherein said palivizumab or antigen-binding fragment thereof is at a concentration of 103±3 mg/ml.
9. The method of claim 3 or 4 , wherein said palivizumab or antigen-binding fragment thereof is at a concentration of at least 100 mg/ml.
10. The method of claim 9 , wherein said palivizumab or antigen-binding fragment thereof is at a concentration of 103±3 mg/ml.
11. The method of claim 1 , wherein the histidine is at a concentration of 1 mM to 100 mM or 10 mM to 50 mM.
12. The method of claim 1 , wherein the histidine is at a concentration of 20 mM to 30 mM.
13. The method of claim 1 or 2 , wherein the histidine is at a concentration of 23 mM to 27 mM.
14. The method of claim 1 , wherein the formulation comprises an excipient other than a surfactant.
15. The method of claim 14 , wherein the excipient is glycine.
16. The method of claim 1 or 2 , wherein the formulation is substantially free of surfactants and inorganic salts.
17. The method of claim 3 or 4 , wherein the formulation is substantially free of surfactants and inorganic salts.
18. The method of claim 1 or 2 , wherein the formulation is substantially free of surfactants, inorganic salts and other excipients.
19. The method of claim 3 or 4 , wherein the formulation is substantially free of surfactants, inorganic salts and other excipients.
20. The method of claim 6 , wherein the formulation is substantially free of surfactants, inorganic salts and other excipients.
21. The method of claim 9 , wherein the formulation is substantially free of surfactants, inorganic salts and other excipients.
22. The method of claim 1 or 2 , wherein the formulation does not contain mannitol.
23. The method of claim 1 or 2 , wherein the formulation has a pH of between about 5.5 to about 7.0.
24. The method of claim 1 or 2 , wherein the formulation has a pH of between about 5.5 to about 6.5.
25. The method of claim 3 or 4 , wherein the formulation has a pH of about 6.0.
26. The method of claim 6 , wherein the formulation has a pH of about 6.0.
27. The method of claim 9 , wherein the formulation has a pH of about 6.0.
28. The method of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 20° C. to 24° C. for at least 1 year as determined by HPSEC.
29. The method of claim 3 or 4 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 20° C. to 24° C. for at least 1 year as determined by HPSEC.
30. The method of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 38° C. to 42° C. for at least 60 days as determined by HPSEC.
31. The method of claim 30 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 38° C. to 42° C. for no more than 120 days as determined by HPSEC.
32. The method of claim 3 or 4 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 38° C. to 42° C. for at least 60 days as determined by HPSEC.
33. The method of claim 32 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 38° C. to 42° C. for no more than 120 days as determined by HPSEC.
34. The method of claim 1 or 2 , wherein the aqueous palivizumab formulation contains no more than 3% aggregation by weight protein as measured by HPSEC.
35. The method of claim 3 or 4 , wherein the aqueous palivizumab formulation contains no more than 3% aggregation by weight protein as measured by HPSEC.
36. The method of claim 1 or 2 , wherein the stable aqueous palivizumab formulation contains equal to or more than 98% of the total protein in a single peak as determined by HSPEC and contains no other single peaks having more than 2% of total protein each.
37. The method of claim 3 or 4 , wherein the stable aqueous palivizumab formulation contains equal to or more than 98% of the total protein in a single peak as determined by HSPEC and contains no other single peaks having more than 2% of total protein each.
38. The method of claim 1 or 2 , wherein the aqueous carrier is distilled water.
39. The method of claim 3 or 4 , wherein the aqueous carrier is distilled water.
40. The method of claim 3 or 4 , wherein the formulation has a pH of about 6.0, the aqueous carrier is distilled water, and said palivizumab or palivizumab antigen-binding fragment is at a concentration of 103±3 mg/ml.
41. The method of claim 19 , wherein the formulation has a pH of 6.0, the aqueous carrier is distilled water, and said palivizumab or palivizumab antigen-binding fragment is at a concentration of 103±3 mg/ml.
42. The method of claim 40 , wherein the human subject is an elderly human, a human with cystic fibrosis, a human with congenital immunodeficiency or acquired immunodeficiency, or a human who has had a bone marrow transplant.
43. The method of claim 40 , wherein the human subject is a human infant.
44. The method of claim 40 , wherein the human subject is a human infant born prematurely or a human infant at high risk for hospitalization for a RSV infection.
45. The method of claim 40 , wherein the human subject is a human with bronchopulmonary dysplasia or congenital heart disease.
46. The method of claim 40 , wherein the formulation is administered to the human subject intramuscularly.
47. A method for preventing serious lower respiratory tract disease caused by RSV in pediatric patients, comprising administering to a pediatric patient an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) 103±3 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of 25 mM; and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of 6.0 does not contain mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.